What is the doxorubicin and olaratumab regimen for the treatment of metastatic soft tissue sarcoma?

Updated: Apr 29, 2019
  • Author: from Memorial Sloan-Kettering - Mrinal M Gounder, MD; Chief Editor: Edwin Choy, MD, PhD  more...
  • Print


Olaratumab 15 mg/kg IV infused over 60 min on days 1 and 8 plus

Doxorubicin 75 mg/m2 on day 1

Repeat every 21 d

Administer olaratumab in combination with doxorubicin for first 8 cycles

After the first 8 cycles, continue with olaratumab every 21 d until disease progression or unacceptable toxicity

Eli Lilly and Company announced olaratumab will be withdrawn from the global market. Withdrawal was based on results of the phase III ANNOUNCE trial which olaratumab in combination with doxorubicin did not improve survival in patients with advanced or metastatic STS compared to doxorubicin alone. Lilly is establishing a program to ensure current patients will have access to olaratumab with limited interruption after it is withdrawn from the global market. [27]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!